Summary of Key Points
Innovative drugs have recently seen a rebound, but despite positive developments this year (such as policy support and corporate R&D progress), their stock prices have remained low. This rebound may be related to two key factors. To determine whether the rally will continue, it is necessary to consider signals such as the implementation of policies, corporate performance, and capital flows. While the long-term potential of innovative drugs remains, short-term volatility should be watched out for.
1. Why Have Stock Prices of Innovative Drugs Remained Low Despite Positive News This Year?
There have been several positive developments for innovative drugs this year: for example, healthcare negotiations have been more favorable to new drugs (providing longer price protection periods to prevent excessive price cuts), multiple companies' cancer and chronic disease drugs have been approved for market release, and some companies have earned substantial royalties by licensing their drugs to foreign firms. However, stock prices have not increased due to three reasons:
- Cool Market Sentiment: The overall stock market has been volatile this year, with investors preferring sectors that offer more stable returns (such as consumer goods and banking) over the higher-risk, higher-return potential of innovative drugs.
- Capital Flowing to Hot Topics: In the first half of the year, AI and renewable energy were in high demand, drawing investment away from innovative drugs.
- Slow Profit Generation: The R&D process for innovative drugs takes several years and billions of dollars. Even after approval, it takes time to generate profits, so institutions are reluctant to invest heavily in these stocks.
2. What Are the Two Main Drivers Behind the Recent Rebound?
The recent rebound is not without cause and is mainly related to two factors:
- Clearer Policy Support: There have been reports that healthcare negotiations may further relax price restrictions on innovative drugs (for example, allowing new drugs to maintain higher prices in the first few years after launch), giving companies more profit margins and boosting market optimism.
- Capital Returning to Value: After the AI sector experienced a surge, many investors saw innovative drugs as an opportunity to buy at lower prices (with some company stocks falling by more than 30% compared to last year). Additionally, foreign investors are increasing their holdings in Chinese innovative drugs due to their perceived long-term potential.
3. Can the Rebound Continue? It Depends on Three Key Signals
To determine if the rally will continue, watch for the following three indicators:
- Signal 1: Implementation of Policy Benefits: If healthcare negotiations indeed provide more profit margins for innovative drugs (for example, if the announced prices are higher than expected), the rebound is likely to sustain. If it's just speculation, prices may quickly reverse.
- Corporate Performance Improvement: Check whether there is an increase in sales after new drug launches or if new potential drugs have moved into later stages of clinical trials (indicating a closer release date). Poor performance will make it difficult for the rally to continue.
- Capital Inflow: Observe daily trading volumes to see if they are increasing significantly (e.g., by more than 50%) and whether institutional holdings are growing. If the increase is mainly due to individual investors, prices may fall after a short period of gains.
4. What Should Ordinary Investors Think About Innovative Drugs?
The long-term prospects for innovative drugs are promising:
- High Demand: The aging population will require more new drugs for treating cancer and diabetes.
- Government Support: China is aiming to transition from a country that relies on generic drugs to one that develops its own innovative medicines, with policies supporting this goal (e.g., accelerating drug approval processes and providing R&D subsidies).
- Technological Advancements: Advances in AI and gene editing are making drug development faster and more cost-effective.
However, there are also significant short-term risks, such as R&D failures, unexpected price cuts by healthcare authorities, and sudden shifts in market capital flows.
Advice for Investors:
- Ordinary investors should avoid buying individual stocks due to the high risk.
- Consider investing in innovative drug-themed funds to diversify their portfolio.
- Avoid buying at peak prices; wait for a pullback before making a purchase.
- If you do invest, hold for the long term (at least 3–5 years) and avoid selling based on short-term fluctuations.
In summary, the recent rebound in innovative drugs is driven by both policy and capital factors. Whether the rally will continue depends on concrete results and the implementation of policies. In the long run, innovative drugs represent a promising investment opportunity, but patience is required, as quick profits are unlikely to be achieved in the short term.